Ribosomal proteins were originally viewed as complements for rRNA in ribosomes but are now emerging as mediators of a variety of checkpoint pathways that link ribosome biogenesis to the cell cycle and other cellular functions. The TOR pathway is a central regulator of ribosome biogenesis at multiple levels. TOR links nutrient availability to cell growth and ribosome synthesis. TOR is activated in multiple human cancers where it drives ribosome biogenesis, which is necessary for the unlimited growth of cancer cells. Another major regulator of ribosome biogenesis in cancer cells is the transcription factor heat shock factor 1 (HSF1) which coordinates the transcription of proteins and RNAs required for translation with many other anabolic processes. In addition, despite the clear link between the production of ribosomes and cancer, some ribosomal proteins can trigger anti-cancer responses. The characterization of the structural motifs that mediate all nonribosomal functions of ribosomal proteins will offer insights to explain the evolution of anticancer responses and new targets to develop new anticancer drugs. In this context, ribosomal marker antibody development becomes an attractive and meaningful project.
Fig.1 Ribosome-free ribosomal proteins (RPs) link ribosome biogenesis to tumor suppressor pathways. (Lessard, 2019)
Anti-ribosomal P (anti-P) antibody in Systemic Lupus Erythematosus (SLE) received considerable attention in recent studies. This antibody recognizes three specific ribosomal phosphoproteins known as P0 (38 kDa), P1 (19 kDa), and P2 (17 kDa). A homologous 22-amino acid C-terminal (C-22) sequence shared by the three proteins is used as the dominant immunoreactive domain to detect anti-P antibodies in SLE. The prevalence of serum anti-P antibodies varies from 15% to 40% in SLE. The anti-P antibody has been suggested to be a specific serological marker for SLE by a few studies regarding antibody specificity and sensitivity. Anti-P antibody was specifically detected in patients with SLE, but not in patients with other rheumatic disorders, patients with chemotherapy-induced cell damage, or healthy controls. A few studies showed that the anti-P antibody was strongly correlated with SLE disease activity, and was observed to be associated with SLE-related neuropsychiatric, renal, and hepatic disorders.
As ribosomes have been found to play important roles in many diseases, many scientists have focused their attention on the ribosome. In this context, ribosomal marker antibody development has become a meaningful project. As an experienced antibody development expert, Creative Biolabs has also been focusing on ribosomes over years. Accumulated from years of practice, our platform has been optimized step by step with up-to-date technologies, advanced equipment, and experienced scientists. With all of these foundations, we are confident in providing customer-satisfied services to global clients.
If you are interested in our ribosomal marker antibody development services or you have any other inquiries about our services, please feel free to contact us for more information.